A submission can be polished, complete, and ready to file.
The facility behind it can still stop the application.
That is not a paperwork problem.
It is a readiness problem.
FDA's FY2025 Report on the State of Pharmaceutical Quality makes that point hard to miss. The report analyzed nearly 10,000 original applications and supplements received during FY2024-2025 that required a facility assessment. As of May 2026, 28% had received a Complete Response Letter. Of those letters, 43% were due to facility withholds. More than half of those facility withholds came from facilities with pre-existing Official Action Indicated or potential Official Action Indicated status.
Those are FDA's numbers. The operating lesson is ours: submission readiness and facility readiness are not separate workstreams.
The application is not the whole product
Teams understandably focus on the submission package. The data. The narrative. The commitments. The response to the agency.
But the submission does not exist in a vacuum. It points back to a real facility, a real quality system, and a real operating history.
If that facility is carrying unresolved problems, the application can inherit them. A clean document cannot outrun a site that is not in a defensible state.
That is especially important when an organization treats manufacturing readiness as something to check after the regulatory team is done. By then, the problem may already be inside the timeline.
Facility status is part of commercialization
A facility with unresolved quality issues is not only a quality concern. It is a commercialization risk.
That means the site, quality, regulatory, technical operations, and commercial teams need one honest readiness picture. Not five separate slide decks that politely avoid one another.
Before a major submission or approval milestone, leadership should be able to answer:
What is the current inspection classification, and are there open commitments that matter to the filing?
Which deviations, investigations, CAPAs, or validation gaps could affect the application or the site assessment?
Is the quality unit involved early enough to challenge an optimistic timeline?
Can the site show current, attributable, complete evidence for the controls it says are working?
Are commercial dates creating pressure to accept operational risk without naming it?
These are not questions for a last-minute readiness meeting. They belong in the plan from the beginning.
The same problems keep surfacing
FDA's report identifies recurring quality concerns, including inadequate investigations, quality control unit responsibilities or procedures that were not written or not followed, and inadequate control of microbiological contamination.
The point is not to turn a report into a new checklist. The point is to recognize the pattern.
When investigations are weak, the organization cannot explain what happened or why the fix should work. When quality responsibilities are unclear, decisions get delayed or quietly made outside the system. When contamination controls are not working, the site carries risk that no polished submission can hide.
Those are operating problems before they become regulatory problems.
Build one readiness picture
The practical move is to stop treating submission readiness and site readiness as two different conversations.
Create one view that connects:
the filing or approval milestone;
the facility's current regulatory status;
open quality-system risks;
remediation and validation work that must be complete;
evidence owners and decision dates; and
the escalation path when the plan starts to slip.
That view does not need to be complicated. It needs to be accurate. It needs named owners. And it needs enough authority behind it to change the plan when the facts change.
This is where leadership matters. A readiness plan that cannot surface bad news early is not a readiness plan. It is a calendar with better formatting.
Do the hard work before the filing window
The uncomfortable question is simple:
If FDA looked at the facility tomorrow, what would the team hope the inspectors did not ask about?
That question is not meant to create theater or panic. It is meant to expose the work that has been deferred, renamed, or placed on a list no one has the capacity to finish.
The answer should drive action before the submission window, not a scramble after the agency raises the issue.
A strong application matters. So does the facility behind it.
Do not treat facility readiness as a downstream check. If the facility can hold the approval, facility readiness belongs in the same conversation as submission readiness.
Clear ownership. An honest risk picture. A plan that moves the work before the filing date.
That is how teams turn readiness from a presentation into something they can defend.
Source: FDA, Report on the State of Pharmaceutical Quality FY2025